---
title: "Recursion Pharmaceuticals, Inc. (RXRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RXRX.US.md"
symbol: "RXRX.US"
name: "Recursion Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T10:39:11.177Z"
locales:
  - [en](https://longbridge.com/en/quote/RXRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RXRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RXRX.US.md)
---

# Recursion Pharmaceuticals, Inc. (RXRX.US)

## Company Overview

Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.recursion.com](https://www.recursion.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.57)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 100 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 11.07% |  |
| Net Profit YoY | 2.61% |  |
| P/B Ratio | 1.47 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1503084291.45 |  |
| Revenue | 66408000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -57.16% | E |
| Profit Margin | -842.93% | E |
| Gross Margin | -1451.08% | E |
| Revenue YoY | 11.07% | B |
| Net Profit YoY | 2.61% | C |
| Total Assets YoY | 2.63% | C |
| Net Assets YoY | 9.72% | B |
| Cash Flow Margin | 57.34% | C |
| OCF YoY | 11.07% | B |
| Turnover | 0.05 | E |
| Gearing Ratio | 23.50% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Recursion Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "11.07%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "2.61%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.47",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1503084291.45",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "66408000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-57.16%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-842.93%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-1451.08%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "11.07%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "2.61%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.63%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.72%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "57.34%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "11.07%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.05",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "23.50%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.69 | 283/386 | - | - | - |
| PB | 1.47 | 138/386 | 2.45 | 2.19 | 1.70 |
| PS (TTM) | 22.63 | 204/386 | 49.63 | 36.75 | 26.06 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 11% |
| Overweight | 2 | 22% |
| Hold | 5 | 56% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.85 |
| Highest Target | 10.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RXRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RXRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RXRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RXRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**